(CLB) Core Laboratories - NYSE
Sector: Energy | Industry: Oil & Gas Equipment & Services | Exchange: NYSE (USA) | Market Cap: 543m USD | Total Return: -7.3% in 12m
Avg Turnover: 7.89M
EPS Trend: -49.1%
Qual. Beats: -1
Rev. Trend: 83.4%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Core Laboratories Inc. (CLB) specializes in reservoir description and production enhancement services for the global oil and gas industry. The company operates through two primary segments: Reservoir Description, which focuses on the laboratory analysis of rock and fluid samples, and Production Enhancement, which provides technologies for well completions, perforations, and stimulations. Beyond traditional fossil fuel services, the firm supports carbon capture, utilization, and storage (CCUS) and geothermal energy projects.
The business model is primarily service-oriented and asset-light compared to heavy equipment providers, as it relies on proprietary analytical data to help clients maximize recovery rates from existing reservoirs. In the Oil & Gas Equipment & Services sector, companies like Core Laboratories are often sensitive to exploration and production (E&P) capital expenditures, which fluctuate based on global commodity prices and rig counts. The company’s focus on reservoir management often results in more stable demand during the production phase of a wells lifecycle compared to the initial drilling phase.
Investors looking for deeper insights into these operational trends may find ValueRay to be a useful tool for further analysis. Founded in 1936 and headquartered in Houston, Texas, Core Laboratories maintains a global footprint, marketing its technical solutions through direct sales and specialized industry distributors.
- Global upstream capital expenditure cycles dictate demand for reservoir characterization services
- International and offshore project expansion drives high-margin reservoir description revenue
- Transition to carbon capture and geothermal projects provides long-term revenue diversification
- Crude oil price volatility impacts client spending on production enhancement technologies
- Adoption of advanced completion diagnostics influences market share in unconventional shale plays
| Net Income: 29.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.21 > 1.0 |
| NWC/Revenue: 20.89% < 20% (prev 24.15%; Δ -3.25% < -1%) |
| CFO/TA 0.06 > 3% & CFO 35.1m > Net Income 29.0m |
| Net Debt (198.4m) to EBITDA (72.4m): 2.74 < 3 |
| Current Ratio: 2.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.1m) vs 12m ago -1.50% < -2% |
| Gross Margin: 17.84% > 18% (prev 16.91%; Δ 0.93% > 0.5%) |
| Asset Turnover: 88.99% > 50% (prev 87.54%; Δ 1.46% > 0%) |
| Interest Coverage Ratio: 4.97 > 6 (EBIT TTM 53.9m / Interest Expense TTM 10.9m) |
| A: 0.19 (Total Current Assets 214.4m - Total Current Liabilities 104.7m) / Total Assets 587.7m |
| B: 0.29 (Retained Earnings 171.4m / Total Assets 587.7m) |
| C: 0.09 (EBIT TTM 53.9m / Avg Total Assets 589.6m) |
| D: 0.86 (Book Value of Equity 268.9m / Total Liabilities 312.6m) |
| Altman-Z'' = 3.69 = AA |
| DSRI: 0.87 (Receivables 115.2m/131.0m, Revenue 524.7m/517.8m) |
| GMI: 0.95 (GM 16.91% / 17.84%) |
| AQI: 1.00 (AQ_t 0.35 / AQ_t-1 0.35) |
| SGI: 1.01 (Revenue 524.7m / 517.8m) |
| TATA: -0.01 (NI 29.0m - CFO 35.1m) / TA 587.7m) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of June 25, 2026, the stock is trading at USD 10.72 with a total of 1,135,071 shares traded. Over the past week, the price has changed by -12.06%, over one month by -26.27%, over three months by -31.71% and over the past year by -7.32%.
Current recommended Stop Loss: 9.90 (which is 7.6% or 1.4 ATR below the current price).
Core Laboratories has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CLB.
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 16.3 | 52.3% |
P/E Trailing = 19.2951
P/E Forward = 19.7628
P/S = 1.034
P/B = 2.0178
P/EG = 1.6717
Revenue TTM = 524.7m USD
EBIT TTM = 53.9m USD
EBITDA TTM = 72.4m USD
Long Term Debt = 114.5m USD (from longTermDebt, last quarter)
Short Term Debt = 12.1m USD (from shortTermDebt, last quarter)
Debt = 221.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 53.4m
Net Debt = 198.4m USD (calculated: Debt 221.2m - CCE 22.8m)
Enterprise Value = 741.0m USD (542.6m + Debt 221.2m - CCE 22.8m)
Interest Coverage Ratio = 4.97 (Ebit TTM 53.9m / Interest Expense TTM 10.9m)
EV/FCF = 39.12x (Enterprise Value 741.0m / FCF TTM 18.9m)
FCF Yield = 2.56% (FCF TTM 18.9m / Enterprise Value 741.0m)
FCF Margin = 3.61% (FCF TTM 18.9m / Revenue TTM 524.7m)
Net Margin = 5.53% (Net Income TTM 29.0m / Revenue TTM 524.7m)
Gross Margin = 17.84% ((Revenue TTM 524.7m - Cost of Revenue TTM 431.1m) / Revenue TTM)
Gross Margin QoQ = 16.19% (prev 18.13%)
Tobins Q-Ratio = 1.26 (Enterprise Value 741.0m / Total Assets 587.7m)
Interest Expense / Debt = 4.91% (Interest Expense 10.9m / Debt 221.2m)
Taxrate = 31.36% (13.5m / 43.1m)
NOPAT = 37.0m (EBIT 53.9m * (1 - 31.36%))
Current Ratio = 2.05 (Total Current Assets 214.4m / Total Current Liabilities 104.7m)
Debt / Equity = 0.82 (Debt 221.2m / totalStockholderEquity, last quarter 268.9m)
Debt / EBITDA = 2.74 (Net Debt 198.4m / EBITDA 72.4m)
Debt / FCF = 10.48 (Net Debt 198.4m / FCF TTM 18.9m)
Total Stockholder Equity = 270.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.92% (Net Income 29.0m / Total Assets 587.7m)
RoE = 10.74% (Net Income TTM 29.0m / Total Stockholder Equity 270.3m)
RoCE = 14.02% (EBIT 53.9m / Capital Employed (Equity 270.3m + L.T.Debt 114.5m))
RoIC = 7.84% (NOPAT 37.0m / Invested Capital 472.3m)
WACC = 7.58% (E(542.6m)/V(763.8m) * Re(9.29%) + D(221.2m)/V(763.8m) * Rd(4.91%) * (1-Tc(0.31)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -51.11 | Cagr: -1.40%
[DCF] Terminal Value 73.10% ; FCFF base≈29.0m ; Y1≈25.4m ; Y5≈20.5m
[DCF] Fair Price = 2.84 (EV 329.2m - Net Debt 198.4m = Equity 130.8m / Shares 46.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -49.08 | EPS CAGR: -3.49% | SUE: -2.97 | # QB: -1
Revenue Correlation: 83.38 | Revenue CAGR: 1.14% | SUE: -0.81 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.09 | Chg30d=-37.93% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.18 | Chg30d=-10.00% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=0.54 | Chg30d=-22.30% | Revisions=-20% | GrowthEPS=-28.0% | GrowthRev=-1.1%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=-1.16% | Revisions=-20% | GrowthEPS=+58.3% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -20%